Active, not recruitingPhase 3NCT04573478
Atrasentan in Patients With IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chinook Therapeutics, Inc.
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Atrasentan(drug)
- Enrollment
- 404 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Comprehensive Research Institute, Alhambra, California, United States
- Kidney Disease Medical Group, Glendale, California, United States
- Stanford University, Stanford, California, United States
- University of Florida, Gainesville, Florida, United States
- GA Nephrology Associates, Lawrenceville, Georgia, United States
- NANI Research, LLC, Hinsdale, Illinois, United States
- NANI Research, LLC, Fort Wayne, Indiana, United States
- University of Louisville Physicians- Kidney Disease Program, Louisville, Kentucky, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Intermed Consultants, Minneapolis, Minnesota, United States
- Pelican Point Dialysis - DaVita Clinical Research, Las Vegas, Nevada, United States
- Capital District Renal Physicians, Clifton Park, New York, United States
- Mountain Kidney and Hypertension Associates, Asheville, North Carolina, United States
- Brookview Hills Research Associates, LLC, Winston-Salem, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04573478 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital